These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1621 related articles for article (PubMed ID: 25125077)

  • 1. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
    Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAF score and mortality in NAFLD after up to 41 years of follow-up.
    Hagström H; Nasr P; Ekstedt M; Kechagias S; Stål P; Bedossa P; Hultcrantz R
    Scand J Gastroenterol; 2017 Jan; 52(1):87-91. PubMed ID: 27616339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
    Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
    Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
    BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
    Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
    Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD.
    Önnerhag K; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2014 Sep; 49(9):1111-8. PubMed ID: 24990583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men.
    Hwang YC; Ahn HY; Park SW; Park CY
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1131-1137.e5. PubMed ID: 29158157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
    Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
    Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study.
    Munsterman ID; Smits MM; Andriessen R; van Nieuwkerk CMJ; Bloemena E; Mulder CJJ; Tjwa ETTL; van Geenen EJM
    Scand J Gastroenterol; 2017 Aug; 52(8):881-885. PubMed ID: 28446050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
    Chan WK; Ida NH; Cheah PL; Goh KL
    J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
    Dulai PS; Singh S; Patel J; Soni M; Prokop LJ; Younossi Z; Sebastiani G; Ekstedt M; Hagstrom H; Nasr P; Stal P; Wong VW; Kechagias S; Hultcrantz R; Loomba R
    Hepatology; 2017 May; 65(5):1557-1565. PubMed ID: 28130788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.